指南与共识甲状腺疾病

ATA、EANM、ETA与SNMMI联合声明:甲状腺癌管理中的诊断与诊疗一体化方法

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer.
指南 / 共识 · Thyroid · 2021-06-23

美国甲状腺协会、欧洲核医学协会、欧洲甲状腺协会和核医学与分子影像学会成立跨学会工作组,于2019年确定围手术期风险分层、诊断性放射性碘成像在初始分期中的作用以及放射性碘治疗反应指标三个主题。工作组达成共识:初始管理决策应基于围手术期风险分层,诊断性放射性碘扫描在ATA中危患者中应选择性使用,放射性碘治疗后反应评估应采用一致的半定量报告系统。

要点

  • 初始管理决策应基于围手术期风险分层,包括第八版AJCC分期和改良2009 ATA风险分层。
  • ATA中危患者诊断性放射性碘扫描应选择性使用,而非强制或完全不需要。
  • 放射性碘治疗后反应评估应采用一致的半定量报告系统。

核心结论

  • 初始患者管理决策应基于围手术期风险分层,包括第八版AJCC分期系统预测疾病特异性死亡和改良2009 ATA风险分层系统估计结构性疾病复发,并合理纳入分子诊疗一体化以进一步完善管理建议。
  • ATA中危患者的诊断性放射性碘扫描应选择性使用,而非视为所有该类别患者必须或不需要。
  • 放射性碘治疗后反应评估应采用一致的半定量报告系统,直至可重复且临床实用的定量系统得到验证。

研究设计与样本

  • 美国甲状腺协会、欧洲核医学协会、欧洲甲状腺协会和核医学与分子影像学会成立跨学会工作组,每年确定可能显著影响临床实践的主题并发表专家意见文章。

主要发现

  • 2019年跨学会工作组确定以下主题进行审查和跨学科讨论:围手术期风险分层、诊断性放射性碘成像在初始分期中的作用以及放射性碘治疗反应指标。

关键数值与推荐

  • 初始患者管理决策应基于围手术期风险分层,包括第八版AJCC分期系统预测疾病特异性死亡和改良2009 ATA风险分层系统估计结构性疾病复发。
  • ATA中危患者的诊断性放射性碘扫描应选择性使用。
  • 放射性碘治疗后反应评估应采用一致的半定量报告系统。

临床怎么用

  • 临床中应依据围手术期风险分层制定初始管理决策,合理纳入分子诊疗一体化。
  • 对ATA中危患者选择性使用诊断性放射性碘扫描,避免一律强制或省略。
  • 放射性碘治疗后采用一致的半定量报告系统进行反应评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The American Thyroid Association (ATA), the European Association of Nuclear Medicine, the European Thyroid Association, and the Society of Nuclear Medicine and Molecular Imaging have established an intersocietal working group to address the current controversies and evolving concepts in thyroid cancer management and therapy. The working group annually identifies topics that may significantly impact clinical practice and publishes expert opinion articles reflecting intersocietal collaboration, consensus, and suggestions for further research to address these important management issues. Summary: In 2019, the intersocietal working group identified the following topics for review and interdisciplinary discussion: (i) perioperative risk stratification, (ii) the role of diagnostic radioactive iodine (RAI) imaging in initial staging, and (iii) indicators of response to RAI therapy. Conclusions: The intersocietal working group agreed that (i) initial patient management decisions should be guided by perioperative risk stratification that should include the eighth edition American Joint Committee on Cancer staging system to predict disease specific mortality, the modified 2009 ATA risk stratification system to estimate structural disease recurrence, with judicious incorporation of molecular theranostics to further refine management recommendations; (ii) diagnostic RAI scanning in ATA intermediate risk patients should be utilized selectively rather than being considered mandatory or not necessary for all patients in this category; and (iii) a consistent semiquantitative reporting system should be used for response evaluations after RAI therapy until a reproducible and clinically practical quantitative system is validated.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Gulec SA, Ahuja S, Avram AM, et al. A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. Thyroid. 2021. PMID: 33789450. doi:10.1089/thy.2020.0826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。